PHARMACEUTICAL PRODUCT DEVELOPMENT INC Revenue
PHARMACEUTICAL PRODUCT DEVELOPMENT INC reported Revenue of $415.39 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-02.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2011-11-02
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC revenues for the quarter ending 2011-09-30 was $415.39M, a 13.69% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC revenues for the quarter ending 2011-06-30 was $407.70M, a 10.21% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC revenues for the quarter ending 2011-03-31 was $383.20M, a 10.51% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC revenues for the quarter ending 2010-12-31 was $388.51M, a 8.70% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC revenues for fiscal 2010 was $1.47B, a 3.80% increase from fiscal 2009.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC revenues for fiscal 2009 was $1.42B, a 8.68% decline from fiscal 2008.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC revenues for fiscal 2008 was $1.55B.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2011-09-30 | $415.39M 10-Q · filed 2011-11-02 | $823.10M derived: sum of 2 quarters · filed 2011-11-02 | $1.21B 10-Q · filed 2011-11-02 | $1.59B derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-06-30 | $407.70M 10-Q · filed 2011-08-04 | $790.91M 10-Q · filed 2011-08-04 | $1.18B derived: sum of 3 quarters · filed 2011-08-04 | $1.54B derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-03-31 | $383.20M 10-Q · filed 2011-05-03 | $771.71M derived: sum of 2 quarters · filed 2011-05-03 | $1.14B derived: sum of 3 quarters · filed 2011-11-02 | $1.51B derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-12-31 | $388.51M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $753.88M derived: sum of 2 quarters · filed 2011-11-02 | $1.12B derived: sum of 3 quarters · filed 2011-11-02 | $1.47B 10-K · filed 2011-02-25 |
| 2010-09-30 | $365.38M 10-Q · filed 2011-11-02 | $735.29M derived: sum of 2 quarters · filed 2011-11-02 | $1.08B 10-Q · filed 2011-11-02 | $1.44B derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-06-30 | $369.92M 10-Q · filed 2011-08-04 | $716.69M 10-Q · filed 2011-08-04 | $1.07B derived: sum of 3 quarters · filed 2011-08-04 | $1.41B derived: sum of 4 quarters · filed 2011-08-04 |
| 2010-03-31 | $346.77M 10-Q · filed 2011-05-03 | $704.17M derived: sum of 2 quarters · filed 2011-05-03 | $1.04B derived: sum of 3 quarters · filed 2011-05-03 | $1.40B derived: sum of 4 quarters · filed 2011-05-03 |
| 2009-12-31 | $357.40M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $697.80M derived: sum of 2 quarters · filed 2011-02-25 | $1.05B derived: sum of 3 quarters · filed 2011-02-25 | $1.42B 10-K · filed 2011-02-25 |
| 2009-09-30 | $340.40M 10-Q · filed 2010-11-05 | $695.00M derived: sum of 2 quarters · filed 2010-11-05 | $1.06B 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $354.60M 10-Q · filed 2010-08-06 | $718.97M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | $1.55B 10-K · filed 2011-02-25 |